The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?

Pharmacol Res. 2008 Jul;58(1):1-7. doi: 10.1016/j.phrs.2008.06.001. Epub 2008 Jun 8.

Abstract

Till date, the pharmaceutical industry has failed to bring effective and safe disease modifying osteoarthritic drugs (DMOADs) to the millions of patients suffering from this serious and deliberating disease. We provide a review of recent data reported on the investigation of DMOADs in clinical trials, including compounds inhibiting matrix-metalloproteinases (MMPs), bisphosphonates, cytokine blockers, calcitonin, inhibitors of inducible nitric oxide synthase (iNOS), doxycycline, glucosamine, and diacereine. We discuss the challenges associated with the drug development process in general and with DMOADs in particular, and we advance the need for a new development paradigm for DMOADs. Two central elements in this paradigm are a stronger focus on the biology of the joint and the application of new and more sensitive biomarkers allowing redesign of clinical trials in osteoarthritis.

Publication types

  • Review

MeSH terms

  • Anthraquinones / therapeutic use
  • Antirheumatic Agents / therapeutic use*
  • Calcitonin / therapeutic use
  • Cytokines / antagonists & inhibitors
  • Diphosphonates / therapeutic use
  • Doxycycline / therapeutic use
  • Glucosamine / therapeutic use
  • Humans
  • Matrix Metalloproteinase Inhibitors
  • Nitric Oxide Synthase Type II / antagonists & inhibitors
  • Osteoarthritis / drug therapy*
  • Osteoarthritis / physiopathology

Substances

  • Anthraquinones
  • Antirheumatic Agents
  • Cytokines
  • Diphosphonates
  • Matrix Metalloproteinase Inhibitors
  • diacetylrhein
  • Calcitonin
  • Nitric Oxide Synthase Type II
  • Glucosamine
  • Doxycycline